Valsartan use in pediatric hypertension. - Test2 - elhamkhani - TriplyDB

Valsartan use in pediatric hypertension.

Valsartan use in pediatric hypertension.

http://www.wikidata.org/entity/Q37859743

about

Therapeutic options for the treatment of hypertension in children and adolescents.Bioavailability of valsartan oral dosage forms.Proliferative changes of renal arteriolar walls induced by administration of angiotensin II receptor blocker are frequent in juvenile rats.

P2860

Q35811571-BA3AC301-2FFF-4348-A08C-BAAA88DA52D5 Q39810427-00D65BA2-AE9B-4DF9-8C42-8A6C95AC91A0 Q54614581-32141CB1-3220-4BAA-8974-972E7A51F512

P2860

Valsartan use in pediatric hypertension.

http://www.wikidata.org/entity/Q37859743

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Valsartan use in pediatric hypertension.

@en

Valsartan use in pediatric hypertension.

@nl

type

label

Valsartan use in pediatric hypertension.

@en

Valsartan use in pediatric hypertension.

@nl

prefLabel

Valsartan use in pediatric hypertension.

@en

Valsartan use in pediatric hypertension.

@nl

P1433

Q37859743-B26B00A6-AFDC-40C1-A3CF-84EB615B69EA

P1476

Q37859743-6E033F86-2660-426C-8897-83282525C76E

P2093

Q37859743-197C6993-01C5-4ACC-ADCA-ABDC36D93F1B

P2860

Q37859743-00BCED0F-520A-45B2-913A-2EC70CE79B89

Q37859743-02FB63CB-F8EC-488C-BF62-382BFFE075D8

Q37859743-09614216-4B52-468A-88EA-A228AC760ADB

Q37859743-0C3F4AF9-310D-4621-BB96-E6E8DD1C46E2

Q37859743-1159DE0F-BA96-4D4F-8B80-A95B8BF5D105

Q37859743-1420A2D1-0272-4818-AFB4-C52246673EB0

Q37859743-143BE495-15FB-463F-8642-60283406B7FB

Q37859743-172EDCF8-BAA9-45DC-8961-EB9AC1A92482

Q37859743-179224D6-7B2C-46F4-B244-0C30A8F49E5A

Q37859743-243A983D-6178-4899-9FBA-3CF71099F1A5

P304

Q37859743-9946E067-DC3B-4718-A59A-92AA59578FC7

P31

Q37859743-4F4CDD52-FD41-4159-9E9F-668E4685147A

P356

Q37859743-9ACD90C9-6776-404A-BEC9-B2A9993BA51E

P433

Q37859743-AB51B919-7215-4935-91B1-275AD2B33004

P478

Q37859743-D09D34ED-7F01-4E77-BFCA-326FD723DDF6

P50

Q37859743-1BFAF448-8F69-4B95-A256-25F4F6A39393

P577

Q37859743-BDE99BEE-5123-490F-8CC4-FADA4754BC1F

P698

Q37859743-2EE227AD-9C92-4006-BE6C-849AC084D11B

P356

P1433

Future Cardiology

P1476

Valsartan use in pediatric hypertension

@en

P2093

Kevin E C Meyers

http://www.w3.org/2001/XMLSchema#string

P2860

The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents

Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin

Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth

Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype

Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.

History of the design of captopril and related inhibitors of angiotensin converting enzyme.

Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.

The AT2 receptor--a matter of love and hate.

A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension.

High blood pressure trends in children and adolescents in national surveys, 1963 to 2002.

P304

151-159

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FCA.10.62

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Brittany J Behar

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21453020

http://www.w3.org/2001/XMLSchema#string